SAN FRANCISCO (MedPage Today) -- Second-line chemotherapy with docetaxel for esophagogastric cancer led to a greater than 40% improvement in survival compared with only symptomatic treatment, results of a British study showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment